Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

91.29 +0.78 (+0.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Ther

< Previous 1 2 3 4 5 Next >
Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
Via Benzinga
Where Intra-Cellular Therapies Stands With Analysts
Via Benzinga
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
Via Benzinga
Expert Ratings for Intra-Cellular Therapies
Via Benzinga
Intra-Cellular Therapies's Earnings: A Preview
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are... 
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
Via Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Ratings for Intra-Cellular Therapies
Via Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday. 
Via Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
Via Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Why Intra-Cellular Therapies Climbed Tuesday
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression. 
Via The Motley Fool
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
The company believes it may have the answer for patients with "mixed features." 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.